Citation, DOI, disclosures and article data
At the time the article was created Frank Gaillard had no recorded disclosures.View Frank Gaillard's current disclosures
Dedifferentiated chondrosarcomas (DCS) are malignant high-grade chondrosarcomas with a poor prognosis. They have a bi-morphic histomorphology of conventional chondrosarcoma and a non-cartilaginous high-grade sarcoma.
Dedifferentiated chondrosarcomas can develop in 10-15% of central chondrosarcomas and a rare percentage of peripheral chondrosarcomas 1,2. They have been found in a wide age range from 15-85 years and a median age between 55-60 years if they develop from a central location 1-5. If they originate from peripheral chondrosarcoma they occur slightly earlier. The male gender is more frequently affected 1,2.
The diagnosis of dedifferentiated chondrosarcoma is established histologically 1.
Diagnostic criteria according to the WHO classification of soft tissue and bone tumors (5th edition) 1:
bi-morphic histology of conventional chondrosarcoma and another high-grade sarcoma with a crisp interface
The presence of IDH mutation is a desirable criterion 1.
The most common symptoms of dedifferentiated chondrosarcomas are swelling/palpable mass lesion and pain. About 20% of those tumors are associated with a pathological fracture 1-3.
Dedifferentiated chondrosarcomas are highly malignant neoplasms with a bi-morphic histomorphology consisting of chondrosarcoma of any grade juxtaposed to a high-grade non-cartilaginous sarcoma such as an undifferentiated pleomorphic sarcoma, osteosarcoma, spindle cell sarcoma, and less commonly rhabdomyosarcoma, leiomyosarcoma or angiosarcoma 1,5.
At the time of writing, the etiology of dedifferentiated chondrosarcoma is unknown 1.
Overall and for tumors originating from central chondrosarcoma the following locations are most frequently involved 1-3:
The most common sites of dedifferentiated chondrosarcomas arising from a peripheral chondrosarcoma 1:
Grossly, dedifferentiated chondrosarcomas are characterized by varying proportions of cartilaginous and non-cartilaginous tumor components 1,2. A lobulated form usually characterizes the chondroid component and a bluish-grey color which is located more centrally the sarcomatous component appears pale-yellow to tannish-brown and is usually found in an extraosseous location or near a pathological fracture 1,2.
Under the microscope, dedifferentiated are characterized by a bi-morphic histomorphology and an abrupt transition between cartilaginous and high-grade sarcoma components 1-3,5.
The chondroid or cartilaginous tumor components display features that range anywhere from the appearance of an enchondroma over low-grade to intermediate and high-grade chondrosarcoma 1.
The high-grade component usually displays histological features of undifferentiated pleomorphic sarcoma or osteosarcoma, less frequently those of rhabdomyosarcoma, leiomyosarcoma or angiosarcoma and in very rare occasions squamous, epithelial or adamantinoma-like features 1. The ratio between chondrosarcoma and high-grade sarcoma tumor proportion is highly variable, ranging between 2% and 98% 1.
The immunophenotype of the non-cartilaginous sarcomatous tumor component follows the differentiation line of the corresponding component with the expression of desmin or keratins in some of the tumors. Only a tiny fraction of IDH1 mutations are recognized by mutation-specific IDH1 antibodies and is therefore for limited use concerning the chondrosarcoma component, but the cartilaginous portion shows reactivity to S100 4. The dedifferentiated component of more than half of the tumors shows overexpression of p53 1,4.
Identical TP53 and IDH mutations might be found in conventional chondrogenic and dedifferentiated sarcomatous tumor components and then indicate a common origin of both parts 1.
Radiographic features of dedifferentiated chondrosarcoma resemble those of intermediate to high-grade chondrosarcoma in the majority of cases. In a minority of cases, their appearance is that of low-grade chondrosarcoma. In up to 10-15% of cases there is no radiographic evidence of a chondroid matrix or an underlying chondral tumor and some of those show features of an osteosarcoma 6,7.
A bi-morphic appearance with unmineralized tumor mass within or adjacent to mineralized chondroid tumor components has been described in up to 30% of cases on radiographs and up to 50% of cases on CT 1.
Radiographic features of periosteal chondrosarcomas include the following 6,7:
osteolytic lesion with permeative and destructive areas
intralesional rings-and-arc calcifications
MRI might demonstrate a bi-morphic or biphasic appearance, that is the coexistence of a cartilaginous tumor with a chondroid matrix and a tumor component of an aggressive non-chondral lesion with or without osseous matrix. This includes tumor components with relatively low signal intensities on T2 and relatively uniform and/or inhomogeneous contrast enhancement patterns next to areas of a typical chondroid matrix with high signal intensity on fluid-sensitive sequences with intralesional signal voids and peripheral and/or septal enhancement patterns 6-8.
However, it should be noted, that a bi-morphic or biphasic appearance is not reliable in distinguishing dedifferentiated chondrosarcoma from a secondary peripheral chondrosarcoma or a periosteal chondrosarcoma 9.
The radiological report should include a description of the following 6-9:
tumor size and location (metaphysis, diaphysis)
extension into the medullary cavity
association to the periosteum/periosteal shell
presence of a stalk
presence of metastases
Treatment and prognosis
The prognosis of dedifferentiated chondrosarcoma is poor with an overall 5-year survival rate of well below 30% 1-3,10. Treatment includes surgery with wide or radical resection 10. Radiation therapy and chemotherapy have not yet been shown to improve prognosis 1,3. Large tumor size >8cm, the presence of a pathological fracture, pelvic location, inadequate surgical margins and of course metastases are associated with poor outcomes 1.
Complications include local recurrences and metastases, especially to the lungs 1,3.
History and etymology
Dedifferentiated chondrosarcoma was first described by the American pathologists David C. Dahlin and John W. Beabout in 1971 2,11.
Differential diagnoses of dedifferentiated chondrosarcoma include 6-9:
- 1. Inwards CY, Bloem JL, Hogendoorn PCW. Dedifferentiated chondrosaroma. In: WHO Classification of Tumours Editorial Board. Soft tissue and bone tumours. Lyon (France): International Agency for Research on Cancer; 2020. (WHO classification of tumours series, 5th ed.; vol. 3). https://publications.iarc.fr
- 2. Staals E, Bacchini P, Bertoni F. Dedifferentiated Central Chondrosarcoma. Cancer. 2006;106(12):2682-91. doi:10.1002/cncr.21936 - Pubmed
- 3. Gusho C, Lee L, Zavras A et al. Dedifferentiated Chondrosarcoma: A Case Series and Review of the Literature. Orthop Rev (Pavia). 2022;14(4):35448. doi:10.52965/001c.35448 - Pubmed
- 4. Gong L, Su Y, Zhang W et al. Dedifferentiated Central Chondrosarcoma: A Clinical, Histopathological, and Immunohistochemical Analysis of 57 Cases. Front Med (Lausanne). 2021;8:746909. doi:10.3389/fmed.2021.746909 - Pubmed
- 5. Dehner C, Maloney N, Amini B et al. Dedifferentiated Chondrosarcoma with Minimal or Small Dedifferentiated Component. Mod Pathol. 2022;35(7):922-8. doi:10.1038/s41379-022-01008-8 - Pubmed
- 6. Douis H & Saifuddin A. The Imaging of Cartilaginous Bone Tumours. II. Chondrosarcoma. Skeletal Radiol. 2013;42(5):611-26. doi:10.1007/s00256-012-1521-3 - Pubmed
- 7. Littrell L, Wenger D, Wold L et al. Radiographic, CT, and MR Imaging Features of Dedifferentiated Chondrosarcomas: A Retrospective Review of 174 De Novo Cases. Radiographics. 2004;24(5):1397-409. doi:10.1148/rg.245045009 - Pubmed
- 8. Jain V, Oliveira I, Chavda A, Khoo M, Saifuddin A. MRI Differentiation of Low-Grade and High-Grade Chondrosarcoma of the Shoulder Girdle, Chest Wall and Pelvis: A Pictorial Review Based on 111 Consecutive Cases. Br J Radiol. 2021;94(1126):20201404. doi:10.1259/bjr.20201404 - Pubmed
- 9. Tilden W, Andrei V, O'Donnell P, Saifuddin A. Peripheral and Periosteal Chondrosarcoma: MRI-Pathological Correlation in 58 Cases. Skeletal Radiol. 2022;51(6):1189-99. doi:10.1007/s00256-021-03947-w - Pubmed
- 10. Kozawa E, Nishida Y, Kawai A et al. Clinical Features and Treatment Outcomes of Dedifferentiated and Grade 3 Chondrosarcoma: A Multi-Institutional Study. Cancer Sci. 2022;113(7):2397-408. doi:10.1111/cas.15382 - Pubmed
- 11. Dahlin D & Beabout J. Dedifferentiation of Low-Grade Chondrosarcomas. Cancer. 1971;28(2):461-6. doi:10.1002/1097-0142(197108)28:2<461::aid-cncr2820280227>3.0.co;2-u - Pubmed
- 12. Murphey M, Walker E, Wilson A, Kransdorf M, Temple H, Gannon F. From the Archives of the AFIP: Imaging of Primary Chondrosarcoma: Radiologic-Pathologic Correlation. Radiographics. 2003;23(5):1245-78. doi:10.1148/rg.235035134 - Pubmed
- 13. Varma D, Ayala A, Carrasco C, Guo S, Kumar R, Edeiken J. Chondrosarcoma: MR Imaging with Pathologic Correlation. Radiographics. 1992;12(4):687-704. doi:10.1148/radiographics.12.4.1636034 - Pubmed